Momelotinib – a promising advancement in the management of myelofibrosis in adults with anemia

Overview of attention for article published in Frontiers in oncology, June 2024

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 9,470 followers.

RT @oyefuqi: Alhamdulillah 🙏🏼 Grateful to share our Mini Review that sheds light on the newly approved Momelotinib (JAK1/2 and ACVR1 inhi…

25 Jun 2024

Reply Repost Favourite

RT @oyefuqi: Alhamdulillah 🙏🏼 Grateful to share our Mini Review that sheds light on the newly approved Momelotinib (JAK1/2 and ACVR1 inhi…

25 Jun 2024

Reply Repost Favourite

Alhamdulillah 🙏🏼 Grateful to share our Mini Review that sheds light on the newly approved Momelotinib (JAK1/2 and ACVR1 inhibitor) for treating myelofibrosis in adults. Please give our paper a read here. https://t.co/oCBtvJcUmI https://t.co/THrdcXJGLR

25 Jun 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.